Skip to Content
Search Menu

A new phase 3 trial shows significantly prolonged overall survival for patients with AML

Clinical and biological markers associated with long-term survival for patients with acute myeloid leukemia in remission after chemotherapy in the QUAZAR AML-001 trial of oral AZACITIDINE.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Asiaan liittyvä sisältö

AML Insights – June Update: What’s New in the Field

/ Jan Andreasen
AML

Nordic AML Insights – June Update: Research and EHA Congress

/ Jan Andreasen
AML
Carl Sandén

EHA 2025: Novel Immune Escape Pathway in AML Identified and Successfully Blocked

/ Carl Sandén
AMLEHA25 Play the Video 01:47
Justinas Daraskevicius

EHA 2025: Overcoming Venetoclax Resistance

/ Justinas Daraskevicius
AMLEHA25 Play the Video 02:20
Anne Louise Tølbøll Sørensen

EHA 2025: Nordic AML Group Explores Optimized Regimen for AML Patients

/ Anne Louise Tølbøll Sørensen
AMLEHA25 Play the Video 03:03

Nordic AML Insights: Research and Ph.D. Contributions

/ Jan Andreasen
AML

AML Insights: What’s New in the Field

/ Jan Andreasen
AML
Michael Savona

AML: Oral Decitabine–Cedazuridine Is Equivalent to Intravenous Decitabine

/ Michael Savona
AMLLeukemia Play the Video 08:00

Liposomal Daunorubicin + Cytarabine: Enhanced Synergistic Antineoplastic Effect in AML Treatment

/ Andrea Lenartova / Jan Andreasen
AML
Back to top